Scientific instruments company Waters Corporation (NYSE:WAT) beat Wall Street’s revenue expectations in Q1 CY2026, but sales fell by 12.8% year on year to $1.27 billion. On top of that, next quarter’s revenue guidance ($1.62 billion at the midpoint) was surprisingly good and 3.7% above what analysts were expecting. Its non-GAAP profit of $2.70 per share was 17% above analysts’ consensus estimates.
Is now the time to buy WAT? Find out in our full research report (it’s free for active Edge members).
Waters Corporation (WAT) Q1 CY2026 Highlights:
- Revenue: $1.27 billion vs analyst estimates of $1.21 billion (12.8% year-on-year decline, 4.5% beat)
- Adjusted EPS: $2.70 vs analyst estimates of $2.31 (17% beat)
- Adjusted EBITDA: $507 million vs analyst estimates of $316.9 million (40% margin, 60% beat)
- Revenue Guidance for Q2 CY2026 is $1.62 billion at the midpoint, above analyst estimates of $1.57 billion
- Management slightly raised its full-year Adjusted EPS guidance to $14.50 at the midpoint
- Operating Margin: -3.7%, down from 10.4% in the same quarter last year
- Organic Revenue rose 13% year on year (beat)
- Market Capitalization: $33.65 billion
StockStory’s Take
Waters Corporation’s first quarter saw a strong market response, as the company delivered results ahead of Wall Street’s revenue and earnings expectations despite headline sales declining year over year. Management pointed to robust organic growth in its legacy divisions and better-than-expected early performance from recently acquired Biosciences and Diagnostic Solutions businesses. CEO Udit Batra credited the swift execution of a 180-day integration plan and operational improvements for driving momentum, highlighting that both instrument replacement activity and new product launches contributed meaningfully to the quarter’s outcome.
Looking forward, Waters Corporation’s raised guidance is underpinned by accelerating synergy realization from its recent acquisition, continued product innovation, and the expectation of margin expansion as integration efforts progress. Management is focused on increasing commercial effectiveness, pricing discipline, and localization initiatives—particularly in China—to capture additional growth. CFO Amol Chaubal emphasized that cost actions and operational discipline should support solid margin progression in the second half, while Batra noted, “We are laser-focused on delivering value through execution, innovation launch excellence, and synergy realization.”
Key Insights from Management’s Remarks
Waters Corporation attributed its quarterly performance to rapid integration actions, strong product demand, and early synergy realization from its acquisition, with management highlighting several operational and strategic initiatives that shaped results.
- Integration of BD businesses: The company rapidly began integrating the acquired Biosciences and Diagnostic Solutions divisions, launching a 180-day plan that emphasized operational focus, frequent funnel reviews, and increased commercial activity, which management claims improved sales execution and pipeline quality in the first quarter.
- Organic growth in legacy divisions: The Analytical Sciences division delivered double-digit organic growth, powered by ongoing instrument replacement cycles, broad adoption of new products, and demand for high-resolution mass spectrometry in both pharma and academic/government segments.
- Product innovation and launches: Waters introduced new offerings such as the Microflow LC Chemistry Columns with MaxPeak Premier technology and the omniDAWN Multi Angle Light Scattering Detector. In diagnostics, the BACTEC FXI blood culture system received regulatory approval in Europe, and the BD Onclarity HPV self-collection kit gained FDA clearance in the U.S., addressing unmet needs in cervical cancer screening.
- Commercial discipline and pricing: Management drove immediate improvements in pricing discipline and contract compliance across acquired divisions, identifying significant opportunities in U.S. Diagnostic Solutions contract enforcement and deploying specialized deal desks to capture incremental revenue.
- Localization and market access in China: Actions were taken to localize manufacturing for flow cytometry products in China, aiming to improve market access and compete for local tenders, with further growth expected as these strategies expand across the Biosciences portfolio.
Drivers of Future Performance
Waters Corporation’s outlook reflects expectations for sustained organic growth, synergy capture from recent acquisitions, and ongoing margin expansion supported by operational improvements and product innovation.
- Synergy realization and integration: Management expects continued progress from cross-selling, instrument replacement, and e-commerce initiatives, which are projected to deliver incremental revenue and margin benefits as integration of the acquired businesses matures through the year.
- Product pipeline and new launches: The company believes that recently launched products, such as the BACTEC FXI blood culture system and new chemistry columns, will drive adoption in key end markets, while further launches and expanded service plan attachment are expected to provide additional growth levers, especially in regulated pharma and diagnostics applications.
- Risks and operational headwinds: Waters acknowledged potential challenges including macroeconomic conditions, competitive dynamics (particularly from private equity-backed entrants in microbiology), and ongoing supply chain pressures. Management is also closely monitoring the pace of localization in China and believes this will be critical for capturing local demand and mitigating export restrictions.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be tracking (1) the pace and effectiveness of integration initiatives and synergy capture from the BD acquisition, (2) execution and uptake of new product launches in diagnostics and analytical sciences, and (3) progress in localizing manufacturing and expanding commercial presence in China. We will also monitor margin trends as cost actions and procurement efficiencies begin to impact results.
Waters Corporation currently trades at $345.05, up from $301.88 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.